NKMAX is a biotech company headquartered in South Korea with subsidiaries in Canada and the United States. The company is listed in the Koreans stock Exchange, the Kosdaq.
NKMAX was founded in 2002 (as ATGen) on the belief that ‘Health is the greatest wealth’. The company and its employees are committed to both improving quality of life and saving lives—whether by providing novel diagnostic tests, developing new therapies, or providing the research community with quality proteins and antibodies that are crucial for life science advancements.
NKMAX manufactures and distributes a large selection of recombinant proteins and monoclonal antibodies to over 200 research institutes in over 20 different countries.
The company has also developed and launched an innovative NK Cell function test called NK VUE to help doctors diagnose diseases that are known to affect NK Cell activity. NK VUE bears CE Marking and has been approved by the KFDA and Health Canada.
As of 2016, NKMAX has over 100 employees and keeps growing. The company's vision to save as many lives as possible is further reinforced by NKMAX’s current development of immunotherapies.